Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Diponegoro Archives of Pediatric Gastroenterology, Hepatology, and Nutrition
Anggie Lorenza
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
PERBANDINGAN PLATELET LARGE CELL RATIO (P-LCR) PADA ANAK DENGAN DEMAM DENGUE DAN DEMAM BERDARAH DENGUE Anggie Lorenza; Nahwa Arkhaesi; Hardian Hardian
DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) Vol 7, No 2 (2018): JURNAL KEDOKTERAN DIPONEGORO
Publisher : Faculty of Medicine, Diponegoro University, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (402.407 KB) | DOI: 10.14710/dmj.v7i2.20743

Abstract

Latar Belakang Infeksi virus dengue merupakan penyakit infeksi akut yang disebabkan oleh virus dengue yang memiliki empat serotipe. Salah satu gejala DD dan DBD ialah trombositopenia. Platelet Large Cell Ratio (P-LCR) merupakan salah satu penanda aktivasi trombosit yang berukuran lebih dari 12 fl yang akan meningkat ketika terjadi trombositopenia.Tujuan Membuktikan perbedaan antara nilai P-LCR pada anak dengan demam dengue dan demam berdarah dengueMetode Penelitian observasional analitik dengan cross-sectional. Sampel penelitian ini adalah pasien anak yang terkena DD dan DBD yang dirawat inap di RSUP Dr. Kariadi dan Rumah Sakit Nasional Diponegoro Semarang dengan total jumlah 49 sampel. Uji beda antara nilai P-LCR dengan DD dan DBD menggunakan uji t-tidak berpasangan. Uji regresi linier dilakukan untuk mengetahui pengaruh dominan terhadap nilai P-LCR.Hasil Rerata nilai P-LCR tertinggi didapatkan pada pasien DBD sebesar 42,05 ± 6,34 sedangkan pada nilai P-LCR pada DD hanya sebesar 31,51 ± 6,96. Terdapat perbedaan bermakna antara nilai P-LCR pada DBD dan DD dengan nilai p<0,001. Uji regresi linier menunjukan hanya kelompok DD dan DBD saja yang mempengaruhi terhadap nilai P-LCR dengan nilai p<0,001.Kesimpulan Rerata nilai P-LCR pada DBD lebih tinggi dibandingkan DD
Unlocking The Efficacy of Tetrahydrobiopterin (BH4) Towards Metabolic Profile and Growth Status in Children with Phenylketonuria: A Meta Analysis Rafi Alfian Razan; Nur Aisiyah Widjaja; Anggie Lorenza; Vianca Samara Andhary; Naoval Diza Ananda
Archives of Pediatric Gastroenterology, Hepatology, and Nutrition Vol. 4 No. 3 (2025): APGHN Vol. 4 No. 3 August 2025
Publisher : The Indonesian Society of Pediatric Gastroenterology, Hepatology, and Nutrition

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58427/apghn.4.3.2025.111-128

Abstract

Background: Phenylketonuria (PKU) is one of the most common types of inborn error of metabolism. Low-phenylalanine diet has been the main treatment for children with PKU. However, recent therapeutic alternatives have emerged as a solution in children with PKU in the form of tetrahydrobiopterin (BH4). This meta analysis aims to assess the effectiveness of BH4 in terms of response rate, metabolic profile and growth status. Methods: Meta analysis was conducted by searching databases such as PubMed, ScienceDirect, Cochrane Library, medRxiv, and Scopus based on the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) guidelines. Data synthesis and analyses were conducted using R version 4.5.1 (R Foundation for Statistical Computing). Result: Fifteen studies were involved in this research, consisting of 1280 children (1063 given BH4). Eight studies reported BH4 reduced plasma phenylalanine concentration by around (686.83 mg/day [95% CI 394.85 to 978.82], p <0.001). Additionally, two studies reported a reduction in plasma phenylalanine concentration, measured in mg/kg/day, following BH4 administration. Children given BH4 and low phenylalanine diet combination showed a higher response rate compared to BH4 only (100% vs 76%). Two studies showed no difference in growth outcomes, which remained within the normal range. Conclusion: BH4 shows promise as an adjunct therapy for children with PKU, but confirmation through larger, standardized, long-term studies assessing outcomes such as growth status and long-term neurocognitive outcome is needed.
Co-Authors Hardian Hardian Nahwa Arkhaesi Naoval Diza Ananda Nur Aisiyah Widjaja, Nur Aisiyah Rafi Alfian Razan Vianca Samara Andhary